{"filings":[{"id":526676,"accession_number":"0001213900-26-058997","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2026-05-19T20:05:26+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Onconetix announces 1-for-10 reverse stock split effective May 21, 2026 to meet Nasdaq bid price rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board fixed 1-for-10 reverse split ratio; effective 12:01 a.m. ET on May 21, 2026.","Reverse split reduces outstanding shares from ~11.4M to ~1.14M; no change in authorized shares or par value.","Split intended to regain compliance with Nasdaq $1.00 minimum bid price rule for continued listing.","No fractional shares issued; holders of fractional shares will receive cash compensation based on closing price on May 20, 2026.","Common stock continues trading on Nasdaq Capital Market under symbol ONCO with new CUSIP 68237Q 401."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77005,"accession_number":"0001213900-26-056109","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2026-05-14T00:35:37+00:00","items":["8.01","9.01"],"status":"ready","headline":"Onconetix reports Q1 2026 progress: two Proclarix publications, PRIME study with Labcorp, European expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two peer-reviewed papers published: Schiess et al. in BMC Cancer (371 men) and Athanasiou et al. in Cancers (132 men) reinforce Proclarix performance in reducing unnecessary biopsies.","PRIME multi-center clinical study initiated with Labcorp; first participants enrolled, targeting up to 500 men for U.S. validation.","European commercial expansion: ~100 Proclarix tests performed in UK screening initiative in Q1 2026; collaboration partner identified in Turkey.","Proclarix is a CE-IVD certified blood test for identifying clinically significant prostate cancer, designed to reduce overdiagnosis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95390,"accession_number":"0001213900-26-051575","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Onconetix shareholders approve reverse stock split up to 1-for-10","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split proposal approved with 1,301,918 for, 253,378 against, 1,393 abstentions.","Board may implement one or more splits at ratios between 1:2 and 1:10 within one year, not exceeding 1:100 aggregate.","Adjournment proposal also approved with 1,332,088 for, 223,071 against, 1,530 abstentions.","Reverse split authorized without further stockholder approval; exact ratio to be set by the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95389,"accession_number":"0001213900-26-047577","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Onconetix board: Oakley and Meier resign; Dorf named Chairman; Epstein elected director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Oakley and Thomas Meier resigned from the Board effective April 20, 2026, with no disagreement with management.","Sammy Dorf appointed Chairman of the Board effective April 23, 2026; receives $20,000/year paid quarterly.","Josh Epstein elected as a Class II director effective April 23, 2026; serves on Audit, Compensation, and chairs Nominating and Corp Gov Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108450,"accession_number":"0001213900-26-034902","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Onconetix implements 1-for-5 reverse stock split to maintain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split effective March 25, 2026 at 12:01 a.m. Eastern Time.","Ratio fixed at 1-for-5, reducing outstanding shares from ~3.6M to ~0.7M.","No fractional shares issued; cash compensation based on March 24 closing price.","CUSIP changes to 68237Q 302; stock trades under symbol ONCO on Nasdaq.","Split intended to meet Nasdaq's $1.00 minimum bid price listing requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108446,"accession_number":"0001213900-26-034054","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K/A","filed_at":"2026-03-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Onconetix appoints David White CEO, Sammy Dorf to board; Ramdeen resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David White appointed CEO effective March 18, 2026; monthly base salary of $21,700.","Timothy Ramdeen resigned from board and committees on March 19, 2026; no disagreement.","Sammy Dorf appointed to board and audit committee effective March 19, 2026.","Compensation reductions: Fedasz reduced by $5,000/mo, Oakley reduced by $26,000/mo, effective March 18.","White's employment agreement includes one-year non-compete and confidentiality covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108449,"accession_number":"0001213900-26-033643","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Onconetix appoints David White CEO, adds Sammy Dorf to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David White appointed CEO effective March 18, 2026; monthly salary $21,700 under employment agreement.","Timothy Ramdeen resigned from board effective March 19, 2026; not due to any disagreement.","Sammy Dorf appointed to board and audit committee effective March 19, 2026; brings capital markets and governance experience.","Karina Fedasz remains interim CFO; her monthly compensation reduced by $5,000; Andrew Oakley's reduced by $26,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108448,"accession_number":"0001213900-26-015212","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Onconetix to acquire Realbotix in reverse merger; Realbotix holders to own 75-90%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Onconetix issues shares to Realbotix seller such that seller owns 75%–90% of fully diluted shares based on Net Cash at closing.","Closing requires Onconetix to have at least $12.5M Net Cash and enter a $125M equity line of credit.","Post-closing board: 5 directors with 4 designated by Realbotix and 1 by Onconetix.","Realbotix is an AI humanoid robotics company with U.S. manufacturing, proprietary AI, and multilingual robots.","Termination fee: $500k plus expenses (capped at $500k); additional $1.5M if Buyer Superior Proposal closes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108447,"accession_number":"0001213900-26-013724","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Onconetix shareholders approve reverse stock split (1:2 to 1:50) at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split proposal passed with 562,803 votes for, 123,144 against, 986 abstentions.","Board authorized to implement split at any ratio between 1-for-2 and 1-for-50 on or before Feb 3, 2027.","Adjournment proposal also approved with 567,357 votes for, 118,604 against, 972 abstentions.","Total outstanding shares as of Dec 12, 2025 record date: 1,555,015 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124885,"accession_number":"0001213900-25-120144","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Onconetix boosts interim CEO pay; shareholders OK PIPE issuance for up to 12.8M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim CEO Karina Fedasz receives $45,000 bonus for 2025, payable Jan 2026; base comp increased $5,000/month from Jan 1, 2026.","Annual meeting elects Thomas Meier and Sarah Romano as Class I directors for three-year term.","Shareholders approve PIPE proposals enabling up to ~12.8M shares from Series D (8.8M) and Series E (4.0M) preferred/warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124884,"accession_number":"0001213900-25-119898","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Onconetix subsidiary amends Labcorp license; up to $300k for PRIME study of Proclarix","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proteomedix (wholly owned by Onconetix) amended license with Labcorp for a new validation study of Proclarix (PRIME Study).","Onconetix will pay Labcorp milestone-based payments up to $300,000 total and bear all study costs.","Mid-five-figure payments per enrolled subject batch; fixed per-subject fee if final milestone not met.","Labcorp not required to pay royalties or milestones for use of the risk calculator in this PRIME Study.","Labcorp must provide study results to Onconetix but Onconetix cannot use or disclose without Labcorp's consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124883,"accession_number":"0001213900-25-103351","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Onconetix fixes 2025 annual meeting for Dec 5; shareholder submissions due Nov 10","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting set for Dec 5, 2025 at 10:00 a.m. ET at Ellenoff Grossman & Schole LLP, New York.","Shareholder proposals under Rule 14a-8 must be received by Nov 10, 2025 for inclusion in proxy.","Director nominations and universal proxy notices also due by close of business on Nov 10, 2025.","Meeting is more than 60 days after last year's anniversary, triggering separate deadlines.","No other material events disclosed; filing is procedural governance update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124882,"accession_number":"0001213900-25-095847","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Onconetix secures $6.25M through PIPE of Series E convertible preferred and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 7,813 shares of Series E convertible preferred stock at $1,000 stated value per share.","Series E convertible at $3.8576 per share; warrants to purchase 2,025,223 common shares included.","Total gross proceeds of approximately $6.25 million from institutional investors.","Ownership limitation set at 4.99%; registration rights agreement granted for underlying shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141590,"accession_number":"0001213900-25-091966","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["1.01","1.02","3.02","7.01","9.01"],"status":"ready","headline":"Onconetix raises $12.9M via Series D convertible preferred stock and warrants in PIPE financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company sold 16,099 shares of Series D convertible preferred stock and warrants to purchase 4,362,827 shares of common stock to eleven institutional investors.","Aggregate purchase price of approximately $12.9 million, with about $9.3 million in cash and the balance offsetting amounts owed to Veru Inc. and others.","Series D preferred stock has a stated value of $1,000 per share, convertible into common stock at an initial conversion price of $3.6896 per share.","Company entered into a registration rights agreement with the PIPE investors for resale of underlying common shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141589,"accession_number":"0001213900-25-089845","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Onconetix subsidiary Proteomedix licenses manufacturing IP for PancreaSure test to Immunovia","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proteomedix provides master cell lines and IP for three of five PancreaSure biomarkers.","Immunovia pays $700K total: two $300K payments (Sep 2025, Mar 2026) plus $100K for materials.","Immunovia to pay 3% royalty on net sales of PancreaSure from 2026 through 2032.","Deal enables Immunovia to purchase reagents directly from Proteomedix's supplier.","Onconetix remains focused on commercializing its own Proclarix prostate cancer test."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141588,"accession_number":"0001213900-25-084500","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Onconetix issues $117.6K in promissory notes; amends Veru note to $5.2M, extended to Sept 19","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $58,823.53 principal note to Keystone Capital and $58,823.53 to KCP Fund I, each with $8,823.53 OID, netting $100K total.","Both notes due upon earlier of ELOC proceeds or May 28, 2026, subordinate to existing Veru debt.","Amended Veru note: principal increased by $100K to $5.2M; maturity extended to September 19, 2025.","Veru waived April Veru Note maturity to September 19, 2025 under August 28 waiver agreement.","Notes require mandatory prepayment from subsequent equity offerings (excluding senior lender and Series C preferred proceeds)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141587,"accession_number":"0001213900-25-074952","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["1.01","2.03","5.02","9.01"],"status":"ready","headline":"Onconetix issues $118K Keystone note, extends Veru note to Aug 14, 2025; director resigns","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $117,647 promissory note to Keystone Capital with $17,647 OID, due March 6, 2026 or upon ELOC proceeds.","Amended Veru September note: principal increased $100K to $5.1M, maturity extended to August 14, 2025.","Director Ajit Singh resigned effective August 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.68,"calibrated_materiality_score":0.68,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141586,"accession_number":"0001213900-25-064469","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Onconetix agrees to reverse merger with Ocuvex; Ocuvex holders to own 90% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Onconetix acquires Ocuvex; Ocuvex holders get 90% of combined co, Onconetix holders 10%.","Post-close board: 7 directors (5 Ocuvex, 2 Onconetix); closing targeted Q4 2025.","Series C Preferred conversion price reduced to $3.50 effective through July 31, 2025.","Andrew Oakley elected Lead Independent Director, to receive $36,000/month.","Nasdaq compliance regained; subject to Mandatory Panel Monitor through July 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159440,"accession_number":"0001213900-25-054501","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Onconetix granted Nasdaq continued listing; completes reverse stock split to meet bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel granted continued listing on June 11, 2025, subject to compliance by June 30, 2025.","Company met periodic filing rule by filing Q1 10-Q on June 12, 2025.","Completed 1-for-85 reverse stock split on June 13, 2025 to address bid price requirement.","Expects to demonstrate compliance with bid price rule by close of business June 27, 2025.","Hearing held May 27, 2025; company's request for continued listing was granted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159439,"accession_number":"0001213900-25-053367","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["1.01","2.03","3.03","5.03","7.01","9.01"],"status":"ready","headline":"Onconetix announces 1-for-85 reverse stock split effective June 13 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split 1-for-85 effective June 13, 2025; outstanding shares reduced from ~44.4M to ~521,863.","Split intended to regain Nasdaq minimum $1.00 bid price compliance; no change to authorized shares.","New CUSIP 68237Q203; trading symbol ONCO unchanged.","Promissory note of $147,058.82 issued to Keystone Capital Partners with $22,059 OID, subordinated to Veru debt, due by March 5, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159438,"accession_number":"0001213900-25-051573","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Onconetix shareholders approve reverse stock split ratio range 1:10 to 1:150","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split proposal approved: 11,956,279 For, 4,222,940 Against, 153,929 Abstentions.","Board authorized to select exact ratio (1-for-10 to 1-for-150) anytime within one year of May 30, 2025.","Adjournment proposal also approved: 13,570,278 For, 2,367,590 Against, 395,280 Abstentions.","44,358,422 shares of common stock were outstanding as of the April 14, 2025 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159437,"accession_number":"0001213900-25-046909","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["1.01","2.03","3.01","9.01"],"status":"ready","headline":"Onconetix receives second Nasdaq delisting notice for late 10-Q; hearing set May 27","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice May 20 for failure to timely file Q1 2025 10-Q, adding to existing non-compliance for late 10-K.","Company also faces delisting due to bid price below $0.10 for 10 consecutive days; hearing before Nasdaq Panel scheduled May 27.","Issued $294,117.65 promissory note to Keystone Capital Partners with OID of $44,117.65; due Feb 2026 or upon equity line proceeds.","No assurance Panel will grant stay; stock delisting would follow if unfavorable decision.","Company intends to file 10-K and 10-Q as promptly as possible to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159436,"accession_number":"0001213900-25-037765","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Onconetix receives additional Nasdaq delisting notice for late 10-K; hearing set for May 27","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received April 24, 2025 notice for failing to file FY2024 10-K, violating Listing Rule 5250(c)(1).","Already faces delisting for bid price below $0.10; hearing scheduled May 27, 2025.","Must request stay by May 1, 2025 to delay suspension pending Panel decision.","Company intends to file 10-K promptly but no assurance of panel relief."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159435,"accession_number":"0001213900-25-033295","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Onconetix faces Nasdaq delisting; stock at $0.10 or less for 10 days, hearing requested","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Onconetix on April 14, 2025, that its stock had closing bid of $0.10 or less for ten consecutive trading days.","Trading suspension scheduled for April 23, 2025, unless Nasdaq Hearings Panel grants a stay via requested hearing.","Company intends to request a hearing to stay suspension; no guarantee of continued listing.","Board postponed 2025 annual meeting from June 4, 2025; new date and record date to be announced later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159434,"accession_number":"0001213900-25-029639","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Onconetix signs LOI for business combination with Ocuvex; Ocuvex holders to own ~90%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Non-binding LOI with Ocuvex Therapeutics, a private ophthalmic biopharma company with FDA-approved product and late-stage clinical assets.","Upon closing, Onconetix will issue new shares to acquire all Ocuvex equity; Ocuvex holders to own ~90% of combined company.","Transaction subject to due diligence, definitive agreement, financing, regulatory and stockholder approvals; no assurance of completion.","Onconetix Chairman Andrew J. Oakley states combination will 'immediately expand our reach beyond oncology, enhancing shareholder value.'","Ocuvex President/CEO Anthony W. Amato notes combining will 'broaden access to capital.'"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159433,"accession_number":"0001213900-25-028646","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Executive Chairman Sapirstein resigns; Interim CFO Fedasz appointed Interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Sapirstein resigned as Executive Chairman and Board member, effective March 28, 2025.","Karina Fedasz, 52, previously Interim CFO, appointed Interim CEO effective April 2, 2025.","Fedasz has background in finance, M&A, and capital raising; formerly CFO at IDW Media Holdings and Head of Business Development at Evofem Biosciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177832,"accession_number":"0001013762-25-001260","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Onconetix presents Proclarix data at EAU; 96% sensitivity, 22% biopsy avoidance in Danish cohort","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proclarix evaluated in 808 patients; in targeted subpopulation (n=371), negative test gave 5% csPCa probability vs 14% for %fPSA (p=0.028).","Proclarix avoided 22% of biopsies while missing only 3 of 101 csPCa cases (2 GG2, 1 GG3).","In extended population (n=654, PSA 2-20 ng/mL), sensitivity 96%, specificity significantly higher than %fPSA and ERSPC RC (p<0.001).","Data presented March 23, 2025 at EAU congress in Madrid; study led by Ahmed H. Zedan, MD, PhD of Lillebaelt Hospital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177831,"accession_number":"0001213900-25-024826","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Onconetix to present Proclarix clinical data at EAU congress; study of 800+ patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abstract accepted for 2025 European Association of Urology congress (March 21-24, Madrid).","Presentation titled 'Clinical Performance of Proclarix in Ruling Out Clinically Insignificant or No Prostate Cancer.'","Study includes >800 patients from Lillebaelt Hospital, University Hospital of Southern Denmark.","Proclarix is a biomarker-based blood test; CEO notes potential to reduce biopsies.","No financial terms disclosed; presentation scheduled March 23."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177830,"accession_number":"0001213900-25-018867","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["1.01","5.02","5.08","9.01"],"status":"ready","headline":"Onconetix appoints James Sapirstein as Executive Chairman; former Interim CEO resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Ralph Schiess resigned as Interim CEO and CSO effective Feb 24, 2025; also to leave Proteomedix AG CEO role on May 31, 2025.","James Sapirstein, existing Board member, appointed Executive Chairman; he is also CEO of Entero Therapeutics (Nasdaq: ENTO).","Sapirstein compensated $400/hour for up to 20 hours/week; payment contingent on company securing sufficient capital.","Board expanded from five to six; Andrew Oakley appointed as Class II director; former CFO at Autolus, Sosei, Vectura, Actelion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177829,"accession_number":"0001213900-25-014928","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["1.01","2.03","4.01","5.02","9.01"],"status":"ready","headline":"Onconetix issues $117k promissory note, changes auditor, strategy officer resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered $117,647 promissory note with Keystone Capital; purchase price $100k, due Nov 12, 2025 or earlier from ELOC proceeds.","Appointed MaloneBailey LLP as new independent auditor effective Feb 13, 2025; no prior disagreements or reportable events.","Christian Brühlmann resigned as Chief Strategy Officer on Feb 18, 2025; remains as Chief Business Officer of Proteomedix AG.","Note is subordinate to existing Veru Inc debt obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177828,"accession_number":"0001213900-25-006553","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Onconetix receives Nasdaq bid price deficiency notice; 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice based on closing bid price below $1.00 from Nov 25, 2024 to Jan 10, 2025.","Compliance period ends July 22, 2025; stock remains listed on Nasdaq Capital Market.","If bid price closes at $1.00+ for 10 consecutive days before deadline, compliance achieved.","Company may request a second 180-day period if it meets other listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177827,"accession_number":"0001213900-25-005521","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Onconetix settles IQVIA dispute for $150k, records $0.9M reduction in accounts payable","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Resolved IQVIA dispute with $150k payment, avoiding claimed $1.09M liability.","Mutual release of all claims under the Master Services Agreement; no admission of liability.","Company to reduce accounts payable by approximately $0.9 million as a result of settlement.","Proteomedix subsidiary posted on LinkedIn about Proclarix study for clinically significant prostate cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194537,"accession_number":"0001213900-24-108439","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Onconetix receives Nasdaq deficiency notice for late Q3 filing; resolved by filing on Dec 10","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Dec 6, 2024 for failure to timely file Form 10-Q for Q3 2024.","Filed the Q3 2024 Form 10-Q with SEC on Dec 10, 2024, curing the deficiency.","Rule 5250(c)(1) requires timely periodic reports; company now in compliance.","Press release issued Dec 12, 2024 confirming receipt and subsequent filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194536,"accession_number":"0001213900-24-105072","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Onconetix obtains waiver of October payment to Veru; future payment percentage rises to 25%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Waives Oct 2024 cash receipt payment due Nov 20, 2024 until Onconetix receives at least $97,000 from Keystone equity line.","In exchange, Onconetix increases Veru's share of net proceeds from future financings/strategic transactions to 25% (from 20%) through June 30, 2025.","Onconetix states it lacks sufficient cash reserves to pay the October Cash Receipt Payments on time.","Amendment executed November 26, 2024; extends forbearance terms under existing April 2024 note agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194535,"accession_number":"0001213900-24-089338","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Onconetix auditor EisnerAmper resigns; material weaknesses persist","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EisnerAmper LLP resigned as auditor on Oct 15, 2024, effective upon filing of Q3 2024 10-Q.","EA's audit report for FY2023 included a going-concern explanatory paragraph.","No disagreements during engagement, but material weaknesses in internal controls reported (e.g., segregation of duties, IT controls).","Company provided EA disclosure; EA letter filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194533,"accession_number":"0001213900-24-086655","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K/A","filed_at":"2024-10-09T23:59:59+00:00","items":["3.01","3.02","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Onconetix resolves Nasdaq delisting risk via reverse split & listing approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received delisting notice on Sep 18 for bid price & equity non-compliance; Nasdaq approved initial listing on Sep 19, rendering issues moot.","Effected 1-for-40 reverse stock split effective Sep 24; no fractional shares issued.","Converted all Series A Preferred (142,749 shares) and Series B Preferred (6,741,820 shares) into common stock.","Issued 513,424 units to Altos Venture with warrants; all warrants exercised for additional 154,027 shares.","Post-split shares outstanding ~8.3M; common stock continues trading on Nasdaq under ONCO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194534,"accession_number":"0001213900-24-084866","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Onconetix closes $2.0M PIPE and $25M ELOC for working capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 3,499 Series C preferred shares (stated value $1,000) at $4.5056 conversion price; warrants for 591,856 shares at $4.38.","PIPE includes registration rights, 15% default dividend rate, and 125% mandatory redemption on bankruptcy trigger.","Entered $25M committed equity line of credit (ELOC) with institutional investor for future at-the-market sales.","Net cash proceeds from PIPE $2.0M; financial advisor Tungsten Advisors/Finalis Securities paid $160K fee.","Series C carries no voting rights, 4.99% ownership blocker, and trigger events allowing alternate conversion at discount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210872,"accession_number":"0001213900-24-081482","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["3.01","3.02","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Onconetix effects 1:40 reverse stock split; Nasdaq delisting notice resolved via new listing approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio 1:40 effective Sept. 24, 2024; no fractional shares issued, cash paid in lieu.","Nasdaq delisting notice for bid price non-compliance received Sept. 18; mooted by Sept. 19 approval of new listing application meeting $4 closing bid price.","Issued 142,749 shares to Veru upon conversion of Series A Preferred; 6,741,820 shares to former Proteomedix holders on Series B automatic conversion.","Issued 513,424 units (share + warrant) to Altos plus 154,027 shares on warrant exercise; all exempt from registration.","Post-split shares outstanding: 8,307,051 total (including 2,656 unvested restricted stock)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210871,"accession_number":"0001213900-24-080705","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Onconetix amends forbearance with Veru; extends Note maturity to June 2025, raises payment percentages","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended forbearance extends April 2024 Note forbearance to March 31, 2025; extends September 2024 Note maturity to June 30, 2025.","10% interest accrues on unpaid balances of both notes; monthly cash receipt payments increased from 15% to 25% (effective Oct 20).","20% of net proceeds from financings/asset sales to be paid to Veru (up from 10%); applicable to proceeds after Sept 19, 2024.","If all principal and interest paid in cash by Dec 31, 2024, September Note principal reduced from $5M to $3.5M.","Series A Preferred Stock to convert to common after reverse split; conversion shares to be unrestricted after one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210870,"accession_number":"0001213900-24-080508","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Onconetix announces 1-for-40 reverse stock split effective Sept 24, 2024 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:40 ratio; outstanding shares reduced from ~30.2M to ~755,000 shares.","Effective 12:01 a.m. ET on Sept 24, 2024; common stock continues trading under 'ONCO' with new CUSIP 68237Q104.","Stockholders approved all proposals at Sept 5 annual meeting, including director elections and equity plan increase to 58M shares.","Split intended to help meet Nasdaq $4.00 minimum bid price for initial listing.","No fractional shares issued; cash payment for fractional shares based on Sept 23 closing price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210869,"accession_number":"0001213900-24-077457","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Onconetix shareholders elect directors and approve reverse stock split, equity plan amendments","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Ramdeen and Ajit Singh were elected as Class III directors with 6,238,121 and 6,368,501 votes for, respectively.","Approved reverse stock split at ratio between 1:30 and 1:60, with 12,403,389 votes for.","Approved 2022 Equity Incentive Plan amendment increasing authorized shares by 54,850,000 (58,000,000 total), 4,956,245 votes for.","Approved issuance of up to 5,709,935 shares upon Series A conversion and 269,672,900 shares upon Series B conversion.","Ratified EisnerAmper LLP as independent auditor for FY2024 with 13,323,616 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210868,"accession_number":"0001213900-24-075697","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Onconetix shareholders to vote on Series B conversion, $5M financing at Sept 5 meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting on Sept 5, 2024; vote on conversion of 269.7M shares from Series B Preferred and $5M PMX private placement.","Pro forma shows Series B conversion eliminates $64.2M carrying value of preferred stock and adds 269.7M common shares.","Pro forma also reflects settlement of $5M related party debenture via 20.5M shares and PIO exercise netting $922,749.","If approved, conversion triggers a change of control, requiring full compliance with Nasdaq initial listing criteria.","Pro forma weighted average shares outstanding would be 325.5M vs 22.2M actual; net loss per share widens to $0.08."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210867,"accession_number":"0001213900-24-075008","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Onconetix faces Nasdaq delisting risk; must meet initial listing criteria including $4.00 minimum bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq ruled Proteomedix AG acquisition triggers Change of Control; must satisfy initial listing rules including $4.00 minimum bid price.","Company has until Sept 16, 2024 to regain Bid Price Rule compliance ($1.00 close for 10 days); extension for stockholders' equity runs to Nov 4, 2024.","Board proposes reverse stock split (1-for-30 to 1-for-60) to boost per-share price and meet Nasdaq minimum price and equity requirements.","Failure to comply could lead to delisting; common stock would trade OTC, materially reducing liquidity and capital access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210866,"accession_number":"0001213900-24-066108","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Onconetix sets deadline of Aug 16 for shareholder proposals and director nominations for Sep 5 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for September 5, 2024 at 10:00 AM ET in New York City.","Deadline for Rule 14a-8 shareholder proposals and director nominations is August 16, 2024 at 5:00 PM ET.","Proposals must be delivered to Cincinnati office addressed to corporate secretary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210865,"accession_number":"0001213900-24-061151","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Onconetix closes warrant exercise for $1.11M gross; issues new warrants for 22.4M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $1.11M from exercise of 7,458,642 existing warrants at reduced $0.15/share.","Issued new unregistered warrants to purchase up to 22,375,926 shares at $0.15 per share.","New warrants exercisable only after stockholder approval; one-third 5-year term, two-thirds 24-month.","Net proceeds to be used for working capital and general corporate purposes.","H.C. Wainwright acted as exclusive placement agent for the transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210864,"accession_number":"0001213900-24-060635","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Onconetix raises $1.1M via warrant exercise inducement; issues 22.4M new warrants at $0.15","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing warrants for 7,458,642 shares exercised at reduced price of $0.15 (original $1.09-$2.546).","Gross proceeds of ~$1.118M; net proceeds for working capital and general corporate purposes.","New inducement warrants issued to purchase 22,375,926 shares at $0.15, subject to stockholder approval.","One-third of new warrants have 5-year term, two-thirds have 24-month term from approval.","H.C. Wainwright acted as exclusive placement agent; closing expected July 12, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229276,"accession_number":"0001213900-24-052976","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K/A","filed_at":"2024-06-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Onconetix appoints Karina Fedasz as Interim CFO at $15k/month plus $2.5k signatory fee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective June 10, 2024; consulting agreement term of one year, 30-day termination notice.","Flat fee of $15,000 per month for up to 80 hours; $200/hour for additional hours.","Additional monthly $2,500 for CFO signatory services.","Consultant will oversee accounting, SEC filings (8-K, 10-Q, 10-K), and cash management.","Replaces prior 8-K filing; compensation terms added via this amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229280,"accession_number":"0001213900-24-052469","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Onconetix CFO Bruce Harmon resigns; Karina Fedasz appointed interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bruce Harmon resigned as CFO effective June 8, 2024; receives $66,152.61 severance under release agreement.","Karina M. Fedasz, 51, appointed Interim CFO effective June 10, 2024; CFO Squad LLC engaged for accounting services.","Fedasz previously served as CFO at IDW Media Holdings and Head of Business Development at Evofem Biosciences.","Compensation for Fedasz to be determined later; Harmon's unvested equity forfeited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229279,"accession_number":"0001213900-24-042369","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Onconetix receives Nasdaq deficiency notice for insufficient stockholders' equity; faces potential delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity was $1,404,476 for FY2023, below Nasdaq's $2.5M minimum requirement.","Company must submit a compliance plan to Nasdaq by June 24, 2024.","If plan accepted, Nasdaq may grant extension until November 4, 2024 to regain compliance.","Failure to regain compliance could result in delisting of ONCO common stock.","No immediate effect on listing; company can appeal any rejection decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229278,"accession_number":"0001213900-24-036645","cik":1782107,"company_name":"Onconetix, Inc.","ticker":"ONCO","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Onconetix enters forbearance on $10M note; pauses ENTADFI commercialization","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Forbearance with Veru extends April 2024 note maturity to March 31, 2025; interest at 10% on unpaid balance.","Onconetix to pay Veru 15% of monthly cash receipts from Proteomedix licensing, Proclarix sales, and Labcorp milestones.","Also to pay 10% of net proceeds from any financing or asset sale through March 2025.","Altos debenture amended to extend maturity to October 31, 2024.","Company pauses ENTADFI commercialization, terminates three employees, considers strategic alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1410142.435897436,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-04-26T23:59:59+00:00|229278"}